Atherosclerosis and Lipoproteins |
From the Hyperlipidemia and Atherosclerosis Research Group, Clinical Research Institute of Montreal, Montreal, Quebec, Canada.
Correspondence to Jeffrey S. Cohn, Hyperlipidemia and Atherosclerosis Research Group, Clinical Research Institute of Montreal, 110 Pine Ave W, Montreal, Quebec, Canada H2W 1R7. E-mail cohnj{at}ircm.qc.ca
AbstractTriglyceride-rich lipoprotein (TRL) remnants are formed in the circulation when apolipoprotein (apo) B-48containing chylomicrons of intestinal origin or apoB-100containing VLDL of hepatic origin are converted by lipoprotein lipase, and to a lesser extent by hepatic lipase, into smaller and more dense particles. Compared with their nascent precursors, TRL remnants are depleted of triglyceride, phospholipid, and C apolipoproteins and are enriched in cholesteryl esters and apoE. They can thus be identified, separated, and/or quantified in plasma according to their density, charge, size, specific lipid components, apolipoprotein composition, and/or apolipoprotein immunospecificity. Each of these approaches has contributed to our current understanding of the compositional characteristics of TRL remnants and their potential to promote atherosclerosis. An ongoing search is nevertheless under way for more accurate and clinically applicable remnant lipoprotein assays that will be able to better define coronary artery disease risk in patients with hypertriglyceridemia.
Key Words: atherogenesis triglycerides apolipoproteins lipoproteins assay
This article has been cited by other articles:
![]() |
L. Wang, R. Gill, T. L. Pedersen, L. J. Higgins, J. W. Newman, and J. C. Rutledge Triglyceride-rich lipoprotein lipolysis releases neutral and oxidized FFAs that induce endothelial cell inflammation J. Lipid Res., February 1, 2009; 50(2): 204 - 213. [Abstract] [Full Text] [PDF] |
||||
![]() |
K. Miyauchi, N. Kayahara, M. Ishigami, H. Kuwata, H. Mori, H. Sugiuchi, T. Irie, A. Tanaka, S. Yamashita, and T. Yamamura Development of a Homogeneous Assay to Measure Remnant Lipoprotein Cholesterol Clin. Chem., December 1, 2007; 53(12): 2128 - 2135. [Abstract] [Full Text] [PDF] |
||||
![]() |
H. J. Ting, J. P. Stice, U. Y. Schaff, D. Y. Hui, J. C. Rutledge, A. A. Knowlton, A. G. Passerini, and S. I. Simon Triglyceride-Rich Lipoproteins Prime Aortic Endothelium for an Enhanced Inflammatory Response to Tumor Necrosis Factor-{alpha} Circ. Res., February 16, 2007; 100(3): 381 - 390. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. Okazaki, S. Usui, A. Fukui, I. Kubota, and H. Tomoike Component Analysis of HPLC Profiles of Unique Lipoprotein Subclass Cholesterols for Detection of Coronary Artery Disease Clin. Chem., November 1, 2006; 52(11): 2049 - 2053. [Abstract] [Full Text] [PDF] |
||||
![]() |
C. Imke, B. L. Rodriguez, J. S. Grove, J. R. McNamara, C. Waslien, A. R. Katz, B. Willcox, K. Yano, and J. D. Curb Are Remnant-Like Particles Independent Predictors of Coronary Heart Disease Incidence?: The Honolulu Heart Study Arterioscler. Thromb. Vasc. Biol., August 1, 2005; 25(8): 1718 - 1722. [Abstract] [Full Text] [PDF] |
||||
![]() |
R. J Cheung, E. K Gupta, and M. K Ito Acute Coffee Ingestion Does Not Affect LDL Cholesterol Level Ann. Pharmacother., July 1, 2005; 39(7): 1209 - 1213. [Abstract] [Full Text] [PDF] |
||||
![]() |
P. N. Hopkins, L. L. Wu, S. C. Hunt, and E. A. Brinton Plasma triglycerides and type III hyperlipidemia are independently associated with premature familial coronary artery disease J. Am. Coll. Cardiol., April 5, 2005; 45(7): 1003 - 1012. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. S. Cohn, C. Rodriguez, H. Jacques, M. Tremblay, and J. Davignon Storage of human plasma samples leads to alterations in the lipoprotein distribution of apoC-III and apoE J. Lipid Res., August 1, 2004; 45(8): 1572 - 1579. [Abstract] [Full Text] [PDF] |
||||
![]() |
H. Fukushima, S. Sugiyama, O. Honda, S. Koide, S. Nakamura, T. Sakamoto, M. Yoshimura, H. Ogawa, D. Fujioka, and K. Kugiyama Prognostic value of remnant-like lipoprotein particle levels in patients with coronary artery disease and type ii diabetes mellitus J. Am. Coll. Cardiol., June 16, 2004; 43(12): 2219 - 2224. [Abstract] [Full Text] [PDF] |
||||
![]() |
K. Oi, H. Shimokawa, J. Hiroki, T. Uwatoku, K. Abe, Y. Matsumoto, Y. Nakajima, K. Nakajima, S. Takeichi, and A. Takeshita Remnant Lipoproteins from Patients with Sudden Cardiac Death Enhance Coronary Vasospastic Activity Through Upregulation of Rho-Kinase Arterioscler. Thromb. Vasc. Biol., May 1, 2004; 24(5): 918 - 922. [Abstract] [Full Text] |
||||
![]() |
T.B. Twickler, G.M. Dallinga-Thie, J.S. Cohn, and M.J. Chapman Elevated Remnant-Like Particle Cholesterol Concentration: A Characteristic Feature of the Atherogenic Lipoprotein Phenotype Circulation, April 27, 2004; 109(16): 1918 - 1925. [Full Text] [PDF] |
||||
![]() |
T. B. Twickler, M. J. M. Cramer, G. M. Dallinga-Thie, M. J. Chapman, D. W. Erkelens, and H. P. F. Koppeschaar Adult-Onset Growth Hormone Deficiency: Relation of Postprandial Dyslipidemia to Premature Atherosclerosis J. Clin. Endocrinol. Metab., June 1, 2003; 88(6): 2479 - 2488. [Full Text] [PDF] |
||||
![]() |
S. M. Grundy Low-Density Lipoprotein, Non-High-Density Lipoprotein, and Apolipoprotein B as Targets of Lipid-Lowering Therapy Circulation, November 12, 2002; 106(20): 2526 - 2529. [Full Text] [PDF] |
||||
![]() |
I. Jialal and S. Devaraj Remnant Lipoproteins: Measurement and Clinical Significance Clin. Chem., February 1, 2002; 48(2): 217 - 219. [Full Text] [PDF] |
||||
![]() |
D. T. Stein, S. Devaraj, D. Balis, B. Adams-Huet, and I. Jialal Effect of Statin Therapy on Remnant Lipoprotein Cholesterol Levels in Patients With Combined Hyperlipidemia Arterioscler. Thromb. Vasc. Biol., December 1, 2001; 21(12): 2026 - 2031. [Abstract] [Full Text] [PDF] |
||||
![]() |
T. C. Ooi, M. Cousins, D. S. Ooi, G. Steiner, K. D. Uffelman, K. Nakajima, and I. E. Simo Postprandial Remnant-like Lipoproteins in Hypertriglyceridemia J. Clin. Endocrinol. Metab., July 1, 2001; 86(7): 3134 - 3142. [Abstract] [Full Text] [PDF] |
||||
![]() |
P. J. Nestel, H. Shige, S. Pomeroy, M. Cehun, and J. Chin-Dusting Post-prandial remnant lipids impair arterial compliance J. Am. Coll. Cardiol., June 1, 2001; 37(7): 1929 - 1935. [Abstract] [Full Text] [PDF] |
||||
![]() |
H. W Wilmink, M. B Twickler, J. D. Banga, G. M Dallinga-Thie, H. Eeltink, D.W. Erkelens, T. J Rabelink, and E. S Stroes Effect of statin versus fibrate on postprandial endothelial dysfunction: role of remnant-like particles Cardiovasc Res, June 1, 2001; 50(3): 577 - 582. [Abstract] [Full Text] [PDF] |
||||
![]() |
C. Marcoux, P. N. Hopkins, T. Wang, E. T. Leary, K. Nakajima, J. Davignon, and J. S. Cohn Remnant-like particle cholesterol and triglyceride levels of hypertriglyceridemic patients in the fed and fasted state J. Lipid Res., September 1, 2000; 41(9): 1428 - 1436. [Abstract] [Full Text] |
||||
![]() |
S. Hirany, D. O'Byrne, S. Devaraj, and I. Jialal Remnant-like Particle-Cholesterol Concentrations in Patients with Type 2 Diabetes Mellitus and End-Stage Renal Disease Clin. Chem., May 1, 2000; 46(5): 667 - 672. [Abstract] [Full Text] [PDF] |
||||
|
ATVB Home | Subscriptions | Archives | Feedback | Authors | Help | AHA Journals Home | Search Copyright © 1999 American Heart Association, Inc. All rights reserved. Unauthorized use prohibited. |